摘要
目的 探讨尿激酶联合低分子肝素、华法林治疗次大面积肺栓塞的疗效和安全性.方法 选取2014年5月~2019年5月我院收治的次大面积肺栓塞患者46例,将其随机分为研究组与对照组,每组23例,对照组运用常规的低分子肝素和华法林治疗,研究组运用尿激酶联合低分子肝素、华法林联合抗凝治疗的方式,对两组治疗3d、1周后的数据分别进行记录,并比较临床效果.结果 研究组患者在治疗3d后的心率、呼吸频率略低于对照组(P<0.05),动脉血氧分压、动脉血二氧化碳分压略高于对照组(P<0.05);研究组患者在治疗1周后的心率、呼吸频率明显低于对照组(P<0.05),动脉血氧分压、动脉血二氧化碳分压明显高于对照组(P<0.05);研究组患者治疗后的临床效果明显高于对照组(P<0.05).结论 相对于常规的低分子肝素和华法林治疗方式,尿激酶联合低分子肝素、华法林联合抗凝治疗次大面积肺栓塞的治疗方式在患者的心率、呼吸频率、动脉血氧分压、动脉血二氧化碳分压等方面的治疗上疗效显著,且具有治疗时间短、见效快、安全性高的优势,在次大面积肺栓塞治疗中的应用效果理想,临床上应当进一步推广应用.
Objective To investigate the efficacy and safety of urokinase combined with low molecular weight heparin sodium and warfarin in the treatment of submassive pulmonary embolism.Methods 46 patients with submassive pulmonary embolism admitted and treated in our hospital from May 2014 to May 2019 were selected,and were divided into the study group and the control group by using the random distribution method,with 23 patients in each group.The control group was treated with routine low molecular weight heparin sodium and warfarin,while the study group was treated with urokinase combined with low molecular weight heparin sodium and warfarin combined with anticoagulation.The data of the two groups after three days and one week of treatment were recorded separately,and the clinical effects were compared.Results After three days of treatment,the heart rate and respiratory rate of patients in the study group were slightly lower than those in the control group(P<0.05),and the arterial partial pressure of oxygen and arterial partial pressure of carbon dioxide were slightly higher than those in the control group(P<0.05);After one week of treatment,the heart rate and respiratory rate of patients in the study group were significantly lower than those in the control group(P<0.05),and the arterial partial pressure of oxygen and arterial partial pressure of carbon dioxide were significantly higher than those in the control group(P<0.05);After treatment,the clinical effects of patients in the study group were significantly higher than those in the control group(P<0.05).Conclusion Relative to the routine therapeutic regimen of low molecular weight heparin sodium and warfarin,the therapeutic regimen of urokinase combined with low molecular weight heparin sodium and warfarin combined with anticoagulation in the treatment of submassive pulmonary embolism has significant efficacy on the treatment of patients’heart rate,respiratory rate,arterial partial pressure of oxygen,and arterial partial pressure of carbon dioxide,with the advantag
作者
刘志标
严婕华
黄洪发
LIU Zhibiao;YAN Jiehua;HUANG Hongfa(First Department of Internal Medicine,Traditional Chinese Medicine Hospital of Gaoming District in Foshan,Guangdong,Foshan 528500,China)
出处
《中国医药科学》
2020年第10期53-56,共4页
China Medicine And Pharmacy
关键词
尿激酶联合低分子肝素
华法林治疗
次大面积肺栓塞
安全性
Urokinase combined with low molecular weight heparin sodium
Warfarin therapy
Submassive pulmonary embolism
Safety
